Accel Wealth Management Makes New $310,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Accel Wealth Management purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, HoldingsChannel reports. The firm purchased 45,800 shares of the company’s stock, valued at approximately $310,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. ARK Investment Management LLC grew its position in Recursion Pharmaceuticals by 16.4% during the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after acquiring an additional 4,626,268 shares during the last quarter. State Street Corp grew its holdings in shares of Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. FMR LLC increased its stake in shares of Recursion Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after buying an additional 170,810 shares during the period. Geode Capital Management LLC raised its holdings in Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after buying an additional 656,003 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Recursion Pharmaceuticals by 2.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,140,750 shares of the company’s stock valued at $14,108,000 after buying an additional 43,078 shares during the period. 89.06% of the stock is owned by institutional investors.

Insider Activity at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the transaction, the director now directly owns 7,066,113 shares in the company, valued at $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,894 shares of company stock valued at $279,279 in the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on RXRX shares. KeyCorp decreased their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.75.

Recursion Pharmaceuticals Stock Down 2.7 %

Shares of Recursion Pharmaceuticals stock opened at $7.33 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -4.79 and a beta of 0.85. The company has a 50-day moving average of $6.90 and a 200 day moving average of $6.94. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter last year, the company posted ($0.43) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.